Siemens Healthcare Diagnostics partners with Pfizer to develop
4 February 2014
Siemens Healthcare Diagnostics and Pfizer are partnering to
develop in vitro diagnostic tests for therapeutic products
across Pfizer’s pipeline.
The Siemens Clinical Laboratory (SCL), a high-complexity testing
laboratory focused on advancing personalised medicine, will develop
companion diagnostic tests under the partnership. The collaboration
will leverage Siemens' worldwide leadership in providing clinical
diagnostic solutions for hospital and reference laboratories,
specialty laboratories and point-of-care settings to help enable
Companion diagnostic tests are clinical tests linked to a
specific drug or therapy intended to assist physicians in making
more informed and personalised treatment decisions for their
patients. When used in the drug development process, companion
diagnostics may help pharmaceutical companies improve patient
selection and treatment monitoring, determine the preferred therapy
dosing for patients, and establish a protocol to help maximise the
treatment benefit for patients.
ohn Hubbard, Senior Vice President and Worldwide Head of
Development Operations at Pfizer, said, "This agreement with Siemens
Healthcare Diagnostics is another example of Pfizer's commitment to
develop new precision medicines to address unmet clinical needs."
"Our relationship with Pfizer marks a major milestone in Siemens'
personalised medicine strategy," said Dr. Trevor Hawkins, Senior
Vice President, Strategy & Innovations, Diagnostics Division,
Siemens Healthcare. "We look forward to collaborating with Pfizer to
realise the goal of advancing innovative solutions that change the
way patient care is delivered and, together, shape the future of